0.00Open0.00Pre Close0 Volume0 Open Interest12.00Strike Price0.00Turnover729.83%IV-60.64%PremiumAug 30, 2024Expiry Date4.53Intrinsic Value100Multiplier3DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.6457Delta0.0744Gamma1.38Leverage Ratio-0.3159Theta-0.0008Rho-0.89Eff Leverage0.0025Vega
Inovio Pharmaceuticals Stock Discussion
Inovio Receives Advanced Therapy Medicinal Product Certificate From European Medicines Agency for Quality and Non-Clinical Data for Lead Candidate Ino-3107
• BLA submission on track for INO-3107 in second half of 2024; if approved under accelerated approval pathway, could be first non-surgicaltreatment for recurrent respiratory papillomatosis (RRP)
• Planning initiation of confirmatory trial for INO-3107 based on FDA feedback
• Advancing plans for Phase 3 trial of INO-3112 in combination with LOQTORZITM ...
No comment yet